乙胺丁醇群体药代动力学与药效学:来自结核病治疗3期确证试验
基于Study 31/AIDS CTG A5349试验中1493例受试者3077份血浆样本,采用非线性混合效应模型分析乙胺丁醇药代动力学。糖尿病、较高肌酐清除率和较高体重与清除率增加相关;较高暴露 modestly 与3级及以上不良事件相关并降低结核不良结局风险。6个月对照方案和4个月利福喷丁方案达到95%治愈的目标暴露分别为8.9和25.6 µg·h/mL。
要点
- 乙胺丁醇暴露对疗效的贡献呈方案依赖性,4个月利福喷丁方案需更高暴露目标。
- 体重>55 kg患者标准治疗中减量可能降低毒性但可能损害短程方案疗效。
- 糖尿病、高肌酐清除率和高体重是乙胺丁醇低暴露的危险因素。
核心结论
- 乙胺丁醇暴露的贡献呈方案依赖性,4个月利福喷丁方案需要更高的疗效目标。
- 体重>55 kg患者减量可降低标准治疗毒性,但可能损害短程方案疗效。
研究设计与样本
- 基于3期确证试验Study 31/AIDS Clinical Trials Group A5349的群体药代动力学分析,纳入1493例受试者3077份血浆样本。
- 采用非线性混合效应建模分析乙胺丁醇药代动力学,参数化时间-事件模型评估疗效,逻辑回归评估安全性。
主要发现
- 一室模型加一级消除最好地描述了乙胺丁醇药代动力学,糖尿病、较高肌酐清除率和较高体重与清除率增加相关。
- 较高乙胺丁醇暴露与3级或以上不良事件 modestly 相关,并降低结核相关不良结局风险。
- 模拟显示降低中等(1200至1000 mg)和最高(1600至1200 mg)体重带的剂量可均衡中位暴露,在对照方案中降低毒性风险同时维持疗效,但在利福喷丁方案中可能无法达到目标暴露。
关键数值与推荐
- 6个月对照方案达到95%治愈的目标暴露为8.9 µg·h/mL。
- 4个月利福喷丁方案达到95%治愈的目标暴露为25.6 µg·h/mL。
临床怎么用
- 临床应考虑糖尿病、高肌酐清除率和高体重对乙胺丁醇清除率的影响,关注低暴露风险。
- 在标准6个月方案中,体重>55 kg患者减量可能降低毒性且维持疗效,但在4个月利福喷丁短程方案中需谨慎避免减量导致疗效受损。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ethambutol, a longstanding treatment for tuberculosis (TB), lacks comprehensive pharmacokinetic (PK) data, particularly regarding covariates affecting exposure and their link to treatment outcomes. Using the largest data to date from Study 31/AIDS Clinical Trials Group A5349, we aimed to characterize ethambutol PKs, identify risk factors for lower exposure, quantify relationships between exposure and efficacy and safety outcomes, and explore dosing considerations that optimize risks and benefits. METHODS: We analyzed ethambutol PK data using nonlinear mixed-effect modeling. We evaluated the contribution of ethambutol exposure to efficacy outcomes using parametric time-to-event modeling and safety outcomes using logistic regression. RESULTS: In 1493 participants with 3077 plasma samples, a one-compartment model with first-order elimination best described ethambutol PKs, with diabetes, higher creatinine clearance, and higher weight linked to increased clearance. Higher ethambutol exposure was modestly associated with grade 3 or higher adverse events and a reduced risk of TB-related unfavorable outcomes. Target exposures for 95% cure were 8.9 µg·h/mL in the 6-month control regimen and 25.6 µg·h/mL in the 4-month rifapentine regimen. Simulations showed that reducing doses in middle (1200 to 1000 mg) and highest (1600 to 1200 mg) weight bands could equalize median exposures, lowering toxicity risk while maintaining efficacy in the control regimen, but might not achieve target exposure in the rifapentine regimen. CONCLUSIONS: The contribution of ethambutol exposure is regimen-dependent, with a higher efficacy target required for the 4-month rifapentine regimen. Dose reductions for patients above 55 kg may mitigate toxicity in standard therapy but risk compromising efficacy in the shorter regimen.
引用
- Alkhafaji S, Yang E, Lee K, et al. Ethambutol Population Pharmacokinetics and Pharmacodynamics From a Phase 3 Confirmatory Trial for the Treatment of Tuberculosis. J Infect Dis. 2026. PMID: 42813385. doi:10.1093/infdis/jiag431
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。